Abstract
AM404 [N-(4-hydroxyphenyl)arachidonylamide] and VDM 11 [(5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide] are commonly used to prevent the cellular accumulation of the endocannabinoid anandamide, and thereby to potentiate its actions. However, it has been reported that AM404 can produce an influx of calcium into cells, which might be expected to have deleterious effects on cell proliferation. In the present study, AM404 and VDM 11 were found to reduce C6 glioma cell proliferation with IC50 values of 4.9 and 2.7 µM, respectively. The inhibition of cell proliferation following a 96-h exposure was not accompanied by dramatic caspase activation, and was not prevented by either a combination of cannabinoid and vanilloid receptor antagonists, or by the antioxidant α-tocopherol, suggestive of a non-specific mode of action. Similar results were seen with palmitoylisopropylamide, although this compound only produced significant inhibition of cell proliferation at 30 µM concentrations. AM404 (1 µM), VDM 11 (1 µM) and palmitoylisopropylamide (3–30 µM), i.e. concentrations producing relatively modest effects on cell proliferation per se, reduced the vanilloid receptor-mediated antiproliferative effects of anandamide, as would be expected for compounds preventing the cellular accumulation of anandamide (and thereby access to its binding site on the vanilloid receptor). It is concluded that concentrations of AM404 and VDM 11 that are generally used to reduce the cellular accumulation of anandamide have deleterious effects upon cell proliferation, and that lower concentrations of these compounds may be more appropriate to use in vitro.
Similar content being viewed by others
References
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo, V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300–302
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affnity anandamide transport, as revealed by selective inhibition. Science 277:1094–1097
Chen WC, Huang JK, Cheng JS, Tsai JCR, Chiang AJ, Chou KJ, Liu CP, Jan CR (2001) AM-404 elevates renal intracellular Ca2+, questioning its selectivity as a pharmacological tool for investigating the anandamide transporter. J Pharmacol Toxicol Methods 45:195–198
De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V(2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52–56
De Petrocellis L, Bisogno T, Maccarone M, Davis JB, Finazzi-Agrò A, Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276:12856–12863
Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791–796
Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenbarger RA, Hillard CJ, Abumrad N (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J Biol Chem 276:6967–6973
Fowler CJ, Jacobsson SOP (2002) Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide — targets for drug development? Prost Leuk Ess Fatty Acids 66:193–200
Fowler CJ, Jonsson K-O, Tiger G (2001) Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem Pharmacol 62; 517–526
Fowler CJ, Jonsson KO, Andersson AS, Jacobsson SOP (2002) Non-specific effects of anandamide uptake inhibitors upon C6 glioma cell proliferation. In: 2002 Abstract Viewer/Itinerary Planner: Society for Neuroscience, Washington DC. Program No. 730.7. Available online http://sfn.scholarone.com/itin2002
Glaser ST, Studholme KM, Fatade F, Yazulla S, Abumrad N, Deutsch DG (2002) Is there an anandamide transporter? In: Program of 2002 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington VT, Abstract 9
Högestätt ED, Zygmunt PM (2002) Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66:343–351
Jacobsson SOP, Fowler CJ (2001) Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132:1743–1754
Jacobsson SOP, Wallin T, Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299:951–959
Jan C-R, Jiann B-P. Lu Y-C, Chang H-T, Huang J-K (2002) Effect of olvanil (N-vanillyl-cis-9-octadecenoamide) on cytosolic Ca2+ increase in renal tubular cells. Life Sci 71:3081–3090
Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ (2000) Structure-activity relationships among N-arachidonoylethanolamine (anandamide) head group analogues for the anandamide transporter. J Neurochem 74:2597–2606
Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133:1263–1275
Jordt S-E, Julius D (2002) Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell 108:421–430
Kim M-J, Jo D-G, Hong G-S, Kim BJ, Lai BJ, Cho D-H, Kim K-W, Bandyopadhyay A, Hong Y-M, Kim DH, Cho C, Liu JO, Snyder SH, Jung Y-K (2002) Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death. Proc Natl Acad Sci USA 99:9870–9875
Lambert DM, DiPaolo FG, Sonveaux P, Kanyonyo M, Govaerts SJ, Hermans E, Bueb JL, Delzenne NM, Tschirhart EJ (1999) Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440:266–274
Lastes-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J (2002) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44:23–35
Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agró A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275:31938–31945
Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18
Morita K, Wong DL (2000) Glucocorticoids enhance serum deprivation but not calcium-induced cytotoxicity in rat C6 glioma cells. Cell Biol Int 24:223–228
Patricelli MP, Cravatt BF (2001) Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitamin Horm 62:95–131
Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 96:5802–5807
Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960–967
Ray SK, Wilford GG, Crosby CV, Hogan EL, Banik NL (1999) Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. Brain Res 829:18–27
Wernyj RP, Mattson MP, Christakos S (1999) Expression of calbinding-D28k in C6 glial cells stabilizes intracellular calcium levels and protects against apoptosis induced by calcium ionophore and amyloid β-peptide. Mol Brain Res 64:69–79
Zygmunt PM, Chuang HH, Mavahed P, Julius D, Högestätt ED (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396:39–42
Acknowledgements
The authors are grateful to the Swedish Medical Research Foundation (Grant no. 12158), Konung Gustav V's and Drottning Victorias Foundation, the Swedish Asthma and Allergy Association's Research Foundation, the Swedish Psoriasis Association, the Research Funds of the Medical Odontological Faculty, Umeå University, the Belgian National Fund for Scientific Research and the Université Catholique de Louvain (FSR grant) for their generous financial support. The experiments reported in this paper comply with the current laws of the country (Sweden) in which they were performed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jonsson, KO., Andersson, A., Jacobsson, S.O.P. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol 77, 201–207 (2003). https://doi.org/10.1007/s00204-002-0435-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-002-0435-6